{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:26:52Z","timestamp":1793014012886,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"40","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Current guidance recommends better LDL-C control in patients with elevated Lp(a) as Lp(a) lowering therapies are unavailable. Whether risks attributable to Lp(a) are mitigated in patients with CAD who achieved LDL-C &amp;lt;55 mg\/dL remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multicentre retrospective observational study analysed 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of MACE (cardiac-caused death + nonfatal MI + coronary revascularization in non-culprit segments) was compared according to Lp(a) levels (&amp;lt;30, \u226530, and &amp;lt;50 mg\/dL and \u226550 mg\/dL) and amongst LDL-C strata (&amp;lt;55 mg\/dL vs \u226555 mg\/dL) 8 weeks after PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the 5.1-year observation amongst patients with LDL-C \u226555mg\/dL (n=1069), MACE occurred in 21.3% with risk of MACE increasing with Lp(a) levels (3.9, 7.9, and 11.0 events per 100 person-years for &amp;lt;30, \u226530, and &amp;lt;50 mg\/dL and \u226550 mg\/dL, log-rank p&amp;lt;0.001). Amongst those with LDL-C &amp;lt;55mg\/dL (n=512), the proportion with MACE was lower overall (4.3%, p&amp;lt;0.001). However, elevated Lp(a) levels still identified those at higher risk of MACE (1.4, 4.7, and 7.5 events per 100 person-years in Lp(a) &amp;lt;30, \u226530, and &amp;lt;50 mg\/dL and \u226550 mg\/dL, p&amp;lt;0.001). Standardized 5-year MACE rate was over twice and five times higher in patients with Lp(a) \u226530 and &amp;lt;50 mg\/dL (17.0%: adjusted HR = 3.80, 95% CI = 1.78\u20138.11, p&amp;lt;0.001) and \u226550 mg\/dL (33.4%: adjusted HR = 6.90, 95% CI = 3.53\u201313.46, p&amp;lt;0.001) compared to Lp(a) &amp;lt;30 mg\/dL (5.0%), respectively. The ROC analyses identified Lp(a) \u226528.2 mg\/dL as the threshold for MACE (AUC = 0.68, p&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Whilst lower achieved LDL-C attenuates in part the risk from Lp(a), elevated Lp(a) levels still associate with worse cardiovascular outcomes. The Lp(a) threshold amongst Japanese patients with CAD at risk of recurrent events appears lower than in Caucasian populations which merits further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag446","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:37:54Z","timestamp":1779190674000},"page":"5991-6003","source":"Crossref","is-referenced-by-count":6,"title":["Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-5593","authenticated-orcid":false,"given":"Yu","family":"Kataoka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, School of Public Health, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-4368","authenticated-orcid":false,"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Medicine Monash Health, Victorian Heart Institute (VHI) , Clayton ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Katasako-Yabumoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-1302","authenticated-orcid":false,"given":"Satoshi","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kashiwa Kousei General Hospital , Kashiwa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hosoda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Chikamori Hospital , Kochi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5162-4783","authenticated-orcid":false,"given":"Kota","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Matama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-4317","authenticated-orcid":false,"given":"Masashi","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-7234","authenticated-orcid":false,"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-4932","authenticated-orcid":false,"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"2026102519520584000_ehag446-B1","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/circulationaha.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"2026102519520584000_ehag446-B3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2026102519520584000_ehag446-B4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2026102519520584000_ehag446-B5","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2026102519520584000_ehag446-B6","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"2026102519520584000_ehag446-B7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"2026102519520584000_ehag446-B8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"key":"2026102519520584000_ehag446-B9","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in lipoprotein(a) levels among patients with coronary heart disease: insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies","volume":"85","author":"Barkas","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102519520584000_ehag446-B10","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B11","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026102519520584000_ehag446-B13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102519520584000_ehag446-B14","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2026102519520584000_ehag446-B15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026102519520584000_ehag446-B16","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2026102519520584000_ehag446-B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2026.120684","article-title":"Achieving LDL-C &lt;1.0 mmol\/L and cardiovascular outcomes in patients with coronary artery disease who received percutaneous coronary intervention","volume":"415","author":"Kataoka","year":"2026","journal-title":"Atherosclerosis"},{"key":"2026102519520584000_ehag446-B18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"2026102519520584000_ehag446-B20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.5551\/jat.GL2022","article-title":"Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022","volume":"31","author":"Okamura","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026102519520584000_ehag446-B21","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"2026102519520584000_ehag446-B22","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026102519520584000_ehag446-B23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1253\/circj.CJ-21-1041","article-title":"JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease","volume":"86","author":"Nakano","year":"2022","journal-title":"Circ J"},{"key":"2026102519520584000_ehag446-B25","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jacc.2011.09.077","article-title":"Functional measurement of coronary stenosis","volume":"59","author":"Pijls","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026102519520584000_ehag446-B26","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001038","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"2026102519520584000_ehag446-B27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1253\/circj.CJ-19-1131","article-title":"JCS 2018 guideline on diagnosis of chronic coronary heart diseases","volume":"85","author":"Yamagishi","year":"2021","journal-title":"Circ J"},{"key":"2026102519520584000_ehag446-B29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026102519520584000_ehag446-B30","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1016\/j.jacl.2024.04.122","article-title":"Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study","volume":"18","author":"Bittner","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026102519520584000_ehag446-B31","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B32","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2025.08.043","article-title":"Lipoprotein(a) levels and time to cardiovascular benefit with alirocumab in patients with recent acute coronary syndrome","volume":"86","author":"Ray","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102519520584000_ehag446-B33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"2026102519520584000_ehag446-B34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jacl.2024.12.019","article-title":"Characterization of lipidic plaque features in association with LDL-C&lt;70 mg\/dL and lipoprotein(a) &lt;50 mg\/dL","volume":"19","author":"Shishikura","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026102519520584000_ehag446-B35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.016683","article-title":"Association of lipoprotein(a) with changes in coronary atherosclerosis in patients treated with alirocumab","volume":"17","author":"Koskinas","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026102519520584000_ehag446-B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.amjcard.2021.12.014","article-title":"Impact of lipoprotein(a) as a residual risk factor in long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statins","volume":"168","author":"Takahashi","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026102519520584000_ehag446-B37","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jcin.2022.05.050","article-title":"Impact of high lipoprotein(a) levels on clinical outcomes following peripheral endovascular therapy","volume":"15","author":"Tomoi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2026102519520584000_ehag446-B38","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"2026102519520584000_ehag446-B39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen general population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026102519520584000_ehag446-B40","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"Wong","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026102519520584000_ehag446-B41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2026102519520584000_ehag446-B42"},{"key":"2026102519520584000_ehag446-B43"},{"key":"2026102519520584000_ehag446-B44"},{"key":"2026102519520584000_ehag446-B45"},{"key":"2026102519520584000_ehag446-B46","author":"National J-PCI Registry Annual Data"},{"key":"2026102519520584000_ehag446-B47","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jama.2023.2487","article-title":"Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial","volume":"329","author":"Hong","year":"2023","journal-title":"JAMA"},{"key":"2026102519520584000_ehag446-B48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy vs high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, noninferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"2026102519520584000_ehag446-B49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","article-title":"The hazards of hazard ratios","volume":"21","author":"Hern\u00e1n","year":"2010","journal-title":"Epidemiology"},{"key":"2026102519520584000_ehag446-B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.gloepi.2022.100080","article-title":"A practical guide to handling competing events in etiologic time-to-event studies","volume":"4","author":"Mansournia","year":"2022","journal-title":"Glob Epidemiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag446\/68346643\/ehag446.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/40\/5991\/68346643\/ehag446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/40\/5991\/68346643\/ehag446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T23:52:14Z","timestamp":1792972334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/40\/5991\/8688250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":50,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2026,5,24]]},"published-print":{"date-parts":[[2026,10,26]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag446","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,21]]},"published":{"date-parts":[[2026,5,24]]}}}